Compass Pathways Plc (DE:5Y6)
NASDAQ:5Y6
5Y6 Stock Chart & Stats
€5.55
-€0.46(-9.79%)
At close: 4:00 PM EST
€5.55
-€0.46(-9.79%)
Day’s Range― - ―
52-Week Range€2.10 - €12.90
Previous CloseN/A
Volume0.00
Average Volume (3M)1.02K
Market Cap
€1.76B
Enterprise Value€684.09M
Total Cash (Recent Filing)€466.01M
Total Debt (Recent Filing)€2.83M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 30, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume126
30 Day Avg. Volume1,024
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.54Price Target Upside288.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.65
Revenue Forecast (FY)€2.20M
Bulls Say, Bears Say
Bulls Say
Clinical Dataset & EfficacyLarge, late-stage dataset with unprecedented 26-week blinded follow-up strengthens the regulatory and clinical evidence base. Durable responder rates across two pivotal trials materially reduce clinical outcome uncertainty, support label claims, and increase the probability of payer confidence and long-term adoption.
Regulatory Pathway AccelerationA rolling NDA and an awarded priority voucher materially shorten the formal review timeline and reduce regulatory execution risk. This structural advantage improves the odds of timely approval, enables more concrete commercial planning, and narrows the window for competitor first-mover advantages.
Financial Runway & Low LeverageRecent financings and a multi-year runway provide the company time to complete regulatory work and initial commercialization preparations without immediate funding pressure. Low reported debt lessens near-term solvency risk, allowing resources to focus on launch execution and site build-out.
Bears Say
Pre-revenue With Large Cash BurnThe company remains pre-revenue with deep, persistent negative operating and free cash flow, implying ongoing dependence on external financing. Sustained cash burn elevates dilution and funding risk, and constrains flexibility if commercial or regulatory timelines slip before revenue generation.
Reimbursement/CPT Valuation UncertaintyCategory III CPT status provides only provisional billing; progression to Category I and assignment of durable RVUs is a slow committee-driven process. Delays or low RVU outcomes would weaken provider economics, limit site adoption and constrain revenue even after regulatory approval.
Regulatory & Operational Timing RisksThe final 26-week dataset is required to complete the filing and key procedural questions (AdCom, DEA rescheduling sequencing, REMS specifics) remain open. These structural timing and operational uncertainties can delay launch, complicate training/REMS rollout, and increase execution risk for commercial uptake.
COMPASS Pathways News
5Y6 FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was €2.10 and its highest was €12.90 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is €1.76B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported €0.611 earnings per share for the quarter, beating the consensus estimate of -€0.378 by €0.99.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.33.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of €0.611 in its last earnings report, beating expectations of -€0.378. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in DE:5Y6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.54 (288.17% Upside)
€21.54 (288.17% Upside)
Blogger Sentiment
Neutral
DE:5Y6 Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
457.14%
12-Months-Change
Fundamentals
Return on Equity
-151.02%
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
5Y6 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.View all DE:5Y6 earnings summaries5Y6 Stock 12 Month Forecast
Average Price Target
€21.54
▲(288.17% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Options Prices
Currently, No data available
---